Reuters logo
BRIEF-Sangamo and Bioverativ announce FDA acceptance of IND application for ST-400
October 2, 2017 / 11:53 AM / 20 days ago

BRIEF-Sangamo and Bioverativ announce FDA acceptance of IND application for ST-400

Oct 2 (Reuters) - Bioverativ Inc

* Sangamo and Bioverativ announce FDA acceptance of IND application for ST-400 -- a gene-edited cell therapy candidate -- to treat beta-thalassemia

* Sangamo Therapeutics Inc - ‍expects to open several clinical sites across United States and begin enrolling patients in first half of 2018​

* Sangamo Therapeutics - based on deal terms, Sangamo responsible for conducting ST-400 phase 1/2 clinical trial

* Sangamo Therapeutics - based on deal terms, Bioverativ responsible for subsequent worldwide clinical development, manufacturing, commercialization Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below